Pfizer, Astellas end Caduet agreement in Japan; Novartis' Ultibro tops Advair in COPD study;

> Pfizer Japan and Astellas Pharma have agreed to terminate the Japanese distribution and copromotion agreement for Caduet combo tablets at the end of next March. Report

> New data shows that Novartis' ($NVS) once-daily Ultibro Breezhaler was superior in reducing COPD flare-ups compared with GlaxoSmithKline's ($GSK) Seretide, known as Advair in the U.S. Release

> ThromboGenics' Jetrea has won approval in South Korea. Release

> Mylan ($MYL) will acquire the U.S. rights to DVT drug Arixtra from Aspen. Release

> An FDA advisory committee has recommended against approval of Actavis' ($ACT) Nebivolol/Valsartan fixed-dose combination NDA for the treatment of hypertension. Release

> Omnicom's Adelphi Worldwide has purchased healthcare brand and research agency The Planning Shop international. Story

> Johnson & Johnson ($JNJ) Vision Care is offering a new range of promotional materials designed to help opticians attract, convert and retain contact lens patients. More

And Finally... AmerisourceBergen's ($ABC) new ad campaign uses a mirror concept to illustrate how the company creates a unified brand. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?